Anti-Galectin-9 Antibody P4D2 Resolving Tumor Apoptosis and Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers, particularly malignant mesothelioma, face challenges in effectively inhibiting Galectin-9-mediated cell signaling, which contributes to tumor progression and immune suppression, due to the complex interactions of Galectin-9 with various immune receptors and its role in modulating macrophage polarization.
Innovation Solution
Development of a specific anti-Galectin-9 antibody, referred to as clone P4D2, that binds to the C-terminal carbohydrate recognition domain of Galectin-9, inducing cancer cell apoptosis and modulating macrophage polarization towards an anti-tumor phenotype, thereby inhibiting Galectin-9-mediated cell signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Galectin-9 is used to treat cancer, then tumor cell apoptosis is induced, but immune suppression and macrophage polarization promote tumor progression
Solution Approach 1:
The patent introduces Tim-3 blocking antibodies as intermediaries that prevent Galectin-9 from binding to its receptor Tim-3 on immune cells. This blocks the harmful immune suppression and pro-tumorigenic macrophage polarization effects while preserving the direct apoptotic effect on tumor cells, thereby resolving the contradiction between inducing apoptosis and avoiding immune suppression
Solution Approach 2:
The patent employs different antibodies with specific local targeting: anti-Galectin-9 antibodies that target the N-terminal CRD to induce apoptosis, and anti-Tim-3 antibodies that target the receptor on immune cells to block suppression. This localized targeting of different functional domains allows simultaneous achievement of apoptosis induction and immune activation
2Reliability
If anti-Galectin-9 antibodies are used to inhibit Galectin-9 activity, then tumor progression is reduced, but the complex interactions with immune receptors remain challenging to target
Solution Approach 1:
The patent segments the Galectin-9 system into distinct functional components: the N-terminal CRD responsible for carbohydrate binding and apoptosis induction, the C-terminal CRD involved in immune cell interactions, and the Tim-3 receptor on immune cells. By developing antibodies that specifically target each segment, the complex interactions are simplified into discrete, targetable pathways
Solution Approach 2:
The patent uses Tim-3 blocking antibodies as intermediaries that specifically intercept the Galectin-9/Tim-3 interaction pathway without interfering with other immune receptors. This selective intermediary approach simplifies the complex web of immune receptor interactions by blocking only the critical Galectin-9-mediated suppression pathway
Data Source
AI summary
An antibody targeting Galectin-9 is provided as are methods of using the same treatment of chronic immune conditions such as infections, inflammatory diseases and cancer, in particular malignant mesothelioma.